comprehensive -WSS

comprehensive

author：comprehensive 2025-10-02 21:00:29 - browse：8373

A sign of Lilly on the top of its biotechnology center — coverage from STAT — Adobe

Eli Lilly reported Thursday that its experimental weekly insulin worked as well as daily basal insulin products in two late-stage studies, paving the way for the drug to compete with a similar weekly insulin developed by Novo Nordisk.

In a 52-week trial of type 2 diabetes patients using insulin for the first time, those on the weekly insulin, called efsitora alfa, had a 1.34% reduction in blood sugar levels, while people on the comparator daily insulin degludec, sold as Tresiba by Novo, had a 1.26% lowering. That resulted in patients having blood sugar levels, known as A1C readings, of 6.87% and 6.95%, respectively.

In a separate 26-week trial of type 2 patients who have been using insulin, those on efsitora and the comparator daily insulin glargine, sold by Lilly as Basaglar and Sanofi as Lantus, both saw A1C reductions of 1.07%, resulting in blood sugar levels of 7.12% and 7.11%, respectively.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： More tobacco lobbyists active in statehouses

explore

WSS

Menendez indictment could see pharma lose a key ally

Address the ethical violations that led to 'Three Identical Strangers'

Senator probes 340B programs at Cleveland Clinic, Bon Secours

UnitedHealth financials solid despite Change Healthcare cyberattack

MassMutual is introducing free genetic testing for members

Senator probes 340B programs at Cleveland Clinic, Bon Secours

focus

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Cholera vaccine supply gets boost as demand surges globally

Virginia high school admissions case could be legal follow

Diversity in clinical trials starts with building trust, experts say

What does generative AI mean for health care? We asked experts

Why do women spend more than men on medical expenses?

DIEP, the 'gold standard' of breast reconstruction, is under threat

Data show record exodus of life scientists from academia

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Did you have Obamacare on your GOP debate bingo card?

hotspot

How the Dana

STAT Virtual Event: How to Increase Diversity in Clinical Trials

WHO recommends dropping component of many flu vaccines

Data show record exodus of life scientists from academia

Biogen shutters digital health group, ends Apple study, in cost cutting move

Listen: Who gets the credit for GLP

focus

explore

Wikipedia

hotspot